SAN DIEGO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today reported its second quarter 2025 operating and financial results and reviewed recent business highlights.
JERUSALEM, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended June 30, 2025.
Ribbon-Cutting Marks New Chapter for Hydrogen-Powered Drone Innovation in the Columbia River Gorge
BINGEN, Wash., Aug. 8, 2025 /PRNewswire/ -- Zepher Flight Labs (ZFL), now...
Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of 2025
Initiated ALKAZAR...
Financial Highlights
Produced 3,863 vehicles in Q2Delivered 3,309 vehicles in Q2; up 38.2% compared to Q2 2024Q2 revenue of $259.4 millionQ2 GAAP diluted net loss...
Hey there, my fabulous financial fashionistas! Ready to dive into some juicy money wisdom that’ll have you strutting towards wealth like you own Wall...
MILPITAS, Calif., Aug. 3, 2025 /PRNewswire/ -- Zepp Health Corporation ("Zepp" or the "Company") (NYSE: ZEPP) today announced its unaudited financial results for the...